Question to the Department for Business, Energy and Industrial Strategy:

To ask the Secretary of State for Business, Energy and Industrial Strategy, pursuant to the Answer of 20 October 2022 to Question 62806 on Cannabis: Medical Treatments, with reference to the Government's Life Sciences Vision, published 6 July 2021, if he will make an assessment of the compatibility of the decision not to assess the potential economic merits of establishing a British-based medical cannabis industry with the UK's aspiration to be the world leader for the development, testing, access and uptake of new and innovative treatments and technologies; and if he will make a statement.

In developing the UK's Life Science Vision we have conducted wide engagement across the sector, including those involved with a wide range of therapeutic modalities, to understand matters of regulation, access and uptake of new products.

The Government is confident that it’s broad based strategy, focussed on improving the competitiveness of every aspect of the UK Life Science environment, is the correct approach, and will enhance the UK’s competitiveness across all therapeutic modalities.

As part of BEIS work on regulation for innovation we are reviewing the TIGRR report and will be continuing delivery plans in due course.